핵의학

본문글자크기
  • [Sci Rep.] Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy.

    경북의대 / 정신영, 이상우*

  • 출처
    Sci Rep.
  • 등재일
    2019 Apr 3
  • 저널이슈번호
    9(1):5570. doi: 10.1038/s41598-019-42083-3.
  • 내용

    바로가기  >

    Abstract
    We aimed to determine whether recombinant human thyrotropin (rhTSH) plus 3.7 GBq could replace thyroid hormone withdrawal (THW) plus 5.55 GBq for adjuvant radioactive iodine (RAI) therapy in differentiated thyroid cancer (DTC) patients with T4 or N1b disease. This study was a retrospective study comparing ablation success rate, response to initial therapy, and recurrence-free survival (RFS) of patients with rhTSH plus 3.7 GBq versus those with THW plus 5.55 GBq in 253 DTC patients with T4 or N1b disease. There were no differences in the TSH-stimulated thyroglobulin level, rate of incomplete response after initial treatment, or the RFS between the two treatment strategies. However, thyroid bed uptake on follow-up diagnostic RAI whole-body scanning (WBS) was more frequently observed in the group treated with rhTSH plus 3.7 GBq than in the group with THW plus 5.55 GBq. Adjuvant RAI therapy with rhTSH plus 3.7 GBq had comparable results in the absence of persistent tumor, compared with that with THW plus 5.55 GBq. Although thyroid bed uptake was more frequently observed, rhTSH plus 3.7 GBq may be used instead of THW plus 5.55 GBq for adjuvant RAI therapy in patients with T4 or N1b disease.

     


    Author information

    Jeong SY1,2, Lee SW3,4, Kim WW5,6, Jung JH5,6, Lee WK7, Ahn BC1,8, Lee J1,8.
    1
    Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
    2
    Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
    3
    Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. swleenm@knu.ac.kr.
    4
    Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea. swleenm@knu.ac.kr.
    5
    Department of Breast and Thyroid Surgery, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
    6
    Department of Breast and Thyroid Surgery, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea.
    7
    Medical Research Collaboration Center in KNUH, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
    8
    Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.

  • 편집위원

    분화갑상선암 치료에 방사성요오드 치료시 recombinant human thyrotropin (rhTSH) 와 방사성요오드 용량의 선정에 기초자료가 될 수 있는 연구결과로 T4 및 N1b에서도 rhTSH 이용 저용량의 I-131이 갑상선호르몬중단 및 고용량 방사성요오드 치료와 유사한 효과를 나타낼 수 있음을 확인하였다. 갑상선암의 방사성요오드치료에 이용될 수 있는 임상연구결 갑상선암치료 관련 임상가 및 핵의학의사에게 관심을 끌 수 있는 연구로 생각됨.

    2019-05-28 17:38:42

  • 덧글달기
    덧글달기
       IP : 3.139.82.23

    등록